

OCT 18 2001



UNITED STATES PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/813,463	03/20/2001	Kenneth G. Warren	098810/027 8740

Jane K. Babin
Pillsbury Winthrop LLP
50 Fremont Street
San Francisco, CA 94105

CONFIRMATION NO. 8427

FORMALITIES LETTER



OC000000006506266

Date Mailed: 09/04/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Ngan
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Warren, et al.

Examiner: NYA

Serial No.: 09/813,463

Group Art Unit: 1653

Filed: March 20, 2001

Docket: 098810/027 8740

For: **PEPTIDE SPECIFICITY OF ANTI-MYELIN BASIC PROTEIN AND THE
ADMINISTRATION OF MYELIN BASIC PROTEIN PEPTIDES TO MULTIPLE
SCLEROSIS PATIENTS**

STATEMENT UNDER 37 C.F.R. § 1.821 (f) and (g)

Commissioner of Patents
Washington, D.C. 20231


Sir:

The contents of the paper copy of the SEQUENCE LISTING and computer readable form submitted herewith are the same. The paper copy of the SEQUENCE LISTING and the computer readable form of the SEQUENCE LISTING do not add new matter.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: 10-12-01


Robert M. Bedgood
Reg. No. 43,488

PILLSBURY WINTHROP LLP
50 Fremont Street
San Francisco, CA 94105
(858) 509-4065 Direct Dial
(415) 983-1200 Facsimile


TECH CENTER 1600/2900

OCT 18 2001

RECEIVED

644 1653

RECEIVED



**TRANSMITTAL LETTER
(General - Patent Pending)**

OCT 18 2001

Docket No.
098810/027 8740

Box 1653

In Re Application Of: Warren, et al.

TECH CENTER 1600/2900

Serial No. 09/813,463	Filing Date March 20, 2001	Examiner NYA	Group Art Unit 1653
--------------------------	-------------------------------	-----------------	------------------------

Title: **PEPTIDE SPECIFICITY OF ANTI-MYELIN BASIC PROTEIN AND THE ADMINISTRATION OF MYELIN BASIC PROTEIN PEPTIDES TO MULTIPLE SCLEROSIS PATIENTS**

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is:

- 1) Response to Notice to Comply; 2) Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence; 3) Statement Under 37 C.F.R. 1.821 (f) and (g); 4) Sequence Listing (hard copy); 5) diskette with Sequence Listing; and 6) reply postcard.

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☐ The Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.
 - ☐ Charge the amount of _____
 - ☐ Credit any overpayment.
 - ☐ Charge any additional fee required.

Robert M. Bedgood
Signature

Dated: October 12, 2001

Robert M. Bedgood
Reg. N . 43,488

I certify that this document and fee is being deposited on **October 12, 2001** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Linda Anders
Signature of Person Mailing Correspondence

Linda Anders
Typed or Printed Name of Person Mailing Correspondence

cc: SF Docketing



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Warren, et al.

Examiner: NYA

Serial No.: 09/813,463

Group Art Unit: 1653

Filed: March 20, 2001

Docket: 098810/027 8740

For: **PEPTIDE SPECIFICITY OF ANTI-MYELIN BASIC PROTEIN AND THE
ADMINISTRATION OF MYELIN BASIC PROTEIN PEPTIDES TO MULTIPLE
SCLEROSIS PATIENTS**

TECH CENTER 1600/2900

OCT 18 2001

RECEIVED

RESPONSE TO NOTICE TO COMPLY

Commissioner of Patents
Washington, D.C. 20231

Sir:


Responsive to the communication mailed September 4, 2001, Applicants submit herewith a paper copy and a computer readable form (diskette) of the sequence listing as required under 37 C.F.R. §1.824 (a). The sequence listing is provided in ASCII text on the accompanying diskette. A copy of the notice to comply is attached to this response.

The paper copy and computer readable forms of the sequence listing are identical and do not add new matter. A statement under 37 C.F.R. §1.821 (f) and (g) to that effect is provided. Accordingly, please amend the specification by entering the enclosed sequence listing.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: 10-12-01


Robert M. Bedgood
Reg. No. 43,488